LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Listă Acțiuni・Sana Biotechnology Inc

Sana Biotechnology Inc

Închisă

SectorSănătate

2.86 6.72

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.64

Maxim

2.91

Indicatori cheie
By Trading Economics
Venit	12M -47M
EPS	-0.171
Angajați	142
EBITDA	23M -35M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+264.31% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-215M 746M
Deschiderea anterioară	-3.86
Închiderea anterioară	2.86

Sentimentul știrilor

By Acuity

25%

75%

51 / 344 Clasament în Healthcare

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iun. 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 iun. 2026, 23:45 UTC

Achiziții, Fuziuni, Preluări

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 iun. 2026, 23:43 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 iun. 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 iun. 2026, 22:06 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 iun. 2026, 20:51 UTC

Câștiguri

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 iun. 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 iun. 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 iun. 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 iun. 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 iun. 2026, 18:52 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 iun. 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 iun. 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 iun. 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 iun. 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 iun. 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 iun. 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iun. 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 iun. 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

264.31% sus

Prognoză pe 12 luni

Medie 9.8 USD 264.31%

Maxim 16 USD

Minim 7 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Sana Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

51 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.